A World Without  Limits for  People With  Diabetes Stopping Deadly Infections approximately  4.5  million  episodes of health care- associated infections (HAIs)  each year, causing  16  million  extra days of hospital stay and  37,000  deaths. Another conse- quence: HAIs place significant  cost pressure on hospitals. Nearly  125  years ago, Johnson & Johnson pioneered  ready-to-use surgical dressings that helped keep  pathogens from infecting  wounds. Now, Advanced  Sterilization Products (ASP),  a division of Ethicon, Inc., is  pioneering the reduction of  pathogens from health care  settings with  GLOSAIR ™  area  disinfection products. GLOSAIR ™  helps reduce the  risk of HAIs and is on course to  become a new standard of care.  Studies show that this safe and  user-friendly technology—a  hydrogen peroxide dry-mist  system—is a more effective  method of disinfecting health  care settings, following  cleaning, than sole reliance on  manual application of tradi- tional disinfectants.  “These machines have helped  us maintain a good standard of  cleaning and manage a safe  patient environment,” says Paul Andrews, Housekeeping  Manager, Dorset County  The World Health  Organization estimates that in  Europe, more than  4  million  patients are affected by  Paul Andrews and colleague  Carrole White use a  GLOSAIR ™ 400  System to help reduce  health care-associated  infections at Dorset County  Hospital in England. Since acquiring Gloster  Europe in  2009 , ASP has leveraged its ability to take  GLOSAIR ™  to more markets. A global rollout began with  launches throughout Europe in  2010 ; plans are to launch in  the U.S. in  2011. Hospital, England. The local  emergency hospital has used  GLOSAIR ™ 400  Systems to help  reduce HAI rates. “We’ve  achieved one of the lowest  MRSA rates in the National  Health System since adding  GLOSAIR ™  to our infection- prevention practices,” says  Andrews.  Diabetes is a global epidemic  that’s increasing at an  alarming rate. “One of the  biggest challenges people with  diabetes face is keeping their  blood glucose levels in range,”  says Kenneth Moritsugu, M.D.,  Vice President, LifeScan, Inc.  “Better control can lead to  fewer long-term complica- tions and ultimately can lower  health care costs.” That’s why the Diabetes  Care franchise remains dedi- cated to creating a world  without limits for people with  diabetes, delivering innovative  products and tools that are  easy for health care providers  to teach and give patients  more helpful information. In  2010 , LifeScan began a  global rollout of the  OneTouch $^{®}$ Verio$^{™}$ Blood  Glucose Monitoring System.  This accurate, easy-to-use  system requires no coding and  filters out many common  interferences, reducing the  chance for error. The system  was test-marketed in the  Netherlands with patients on insulin therapy and  launched in Australia and  Europe. Other markets will follow in  2011 . Also in  2010 , Animas  Corporation, a leader in  insulin pump systems, partnered with the Juvenile  Diabetes Research Foundation  to develop a first-generation  partially automated glucose management system, a step toward the goal of revolutionizing treatment of type  1  diabetes.  JOHNSON & JOHNSON 2010 ANNUAL REPORT 18 INFECTION PREVENTION